# Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)

> **NCT02478450** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Q Therapeutics, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** Q-Cells

## Key facts

- **NCT ID:** NCT02478450
- **Lead sponsor:** Q Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478450, "Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02478450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*